Drug intelligence / Profile preview

Neuron012703

Development stage: Preclinical
Lead developer: Targeted Medical Pharma
Modality: Small Molecules
Administration: Oral

Overview

Neuron012703 is an amino acid formulation developed by Targeted Medical Pharma. Classified as a medical food, it is being investigated in a clinical outcomes study for its potential to reduce pain and numbness in patients diagnosed with peripheral neuropathy. The formulation is administered orally, with a regimen of two capsules taken twice daily for sixty days.

Beyond the preview

Go deeper on Neuron012703.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuron012703.

Explore the full profile